Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to $2.3 million.

  • HCW Biologics' Shares Outstanding (Diluted Average) rose 13901.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 13901.27%. This contributed to the annual value of $38.8 million for FY2024, which is 797.0% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Shares Outstanding (Diluted Average) is $2.3 million, which was up 13901.27% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Shares Outstanding (Diluted Average) ranged from a high of $44.7 million in Q1 2025 and a low of $945585.0 during Q2 2024
  • In the last 5 years, HCW Biologics' Shares Outstanding (Diluted Average) had a median value of $35.8 million in 2022 and averaged $25.9 million.
  • In the last 5 years, HCW Biologics' Shares Outstanding (Diluted Average) skyrocketed by 62777.08% in 2022 and then plummeted by 9736.8% in 2024.
  • Over the past 5 years, HCW Biologics' Shares Outstanding (Diluted Average) (Quarter) stood at $18.8 million in 2021, then surged by 90.84% to $35.8 million in 2022, then increased by 0.3% to $35.9 million in 2023, then grew by 7.97% to $38.8 million in 2024, then plummeted by 94.17% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $1.8 million for Q2 2025, and $44.7 million during Q1 2025.